What do systematic reviews say?

Dialectical behavioural therapy or mentalisation‐based therapy vs usual care

• Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 149 participants
  Low

Dialectical behavioural therapy or mentalisation‐based therapy vs usual care

• Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 376 participants
  Low

Dialectical behavioural therapy or mentalisation‐based therapy vs usual care

• Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 225 participants
  Low

Dialectical behavioural therapy or mentalisation‐based therapy vs usual care

The review found no eligible studies for this question.

• Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dialectical behavioural therapy or mentalisation‐based therapy vs usual care

Dialectical behavioural therapy or mentalisation‐based therapy may leads to lower suicide‐related outcomes Measured by: clinicians Timing of outcome… compared with treatment‐as‐usual (low certainty).

• Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
  RR 0.1 [0.04, 0.3]
  3 studies · 218 participants
  Low

Fixed bonded Hyrax appliance followed by U-bow activator therapy vs no treatment

Fixed bonded Hyrax appliance followed by U-bow activator therapy showed no clear difference in canine expansion compared with no treatment; GRADE not reported.

• Orthodontic treatment for posterior crossbites 2021 · Cochrane All outcomes

  12 months after start of treatment
  U-bow activator 3.6 mm vs untreated 1 mm; P<0.001 (no SD reported); significant in favour of treatment
  1 study · 66 participants
  GRADE not reported

Fixed bonded Hyrax appliance followed by U-bow activator therapy vs no treatment

Fixed bonded Hyrax appliance followed by U-bow activator therapy showed no clear difference in molar expansion compared with no treatment; GRADE not reported.

• Orthodontic treatment for posterior crossbites 2021 · Cochrane All outcomes

  12 months after start of treatment
  U-bow activator 5.1 mm vs untreated 0.8 mm; P<0.001 (no SD reported); significant in favour of treatment
  1 study · 66 participants
  GRADE not reported

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 55 participants
  Low

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 55 participants
  Low

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 55 participants
  Low

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 55 participants
  Low

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 55 participants
  Low

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Low